For all statistics, the level of significance for 2-tailed P values was set at ≤0.05. All statistical procedures were carried out by SSPS 17.0 for Windows (SPSS, Chicago, IL). Table 1 lists the patients’ clinical characteristics. All children completed treatment. There was no significant difference in the baseline demographic variables between

learn more the groups, with the exception of mobility. The mobility level differed between the children with mental disability and the total cerebral palsy group (U = 196.00; P < 0.001) and also between the children with spastic and dyskinetic cerebral palsy subtype (U = 1038.00; P = 0.02). Because of limitations related to the clinical diagnoses, it was not always possible to obtain simultaneous scores for the swab tests and the Drooling Quotient at 1 measurement session. The swab testing at baseline could be performed in 109 children and in 100 children at the 8-week assessment. At baseline, the Drooling Quotient was determined in 120 children and at 8 weeks in 109 children. Missing data (14%) occurred at different assessment moments randomly spread over all children. Data of the median submandibular and parotid flow rates, and Drooling

Quotient at baseline and at 8 weeks after injection of all participants are listed in Table 2. Table 3 provides the results between the diagnosis categories at baseline and after submandibular botulinum toxin type A therapy. According to our definition, 93 children responded find protocol fully and 33 children were unresponsive to botulinum toxin type A (Table 4). At baseline, there were neither statistically significant differences between the median submandibular flow

rate (U = 1189.50; P = 0.06) nor the median Drooling Quotient (U = 1302.50; P = 0.20), whereas the difference for the median parotid flow rate was statistically significant (U = 1099.00; P = 0.02) between the children responsive or unresponsive to botulinum toxin type A. Furthermore, in the children responsive to botulinum toxin type A, decrease of submandibular flow rate across time was accompanied with decrease of parotid flow, whereas in children unresponsive to botulinum toxin PRKACG type A, the parotid flow rate increased marginally. The difference in the parotid flow rates over time was statistically significant (F(1;124) = 20.92; P < 0.001) between the those who did and did not respond to therapy. The median parotid flow rates across time between children responsive and unresponsive to botulinum toxin type A are presented in Figure 1. Clinical variables as developmental age (rs = −0.03; P = 0.71), mobility level (rs = 0.08; P = 0.38), and spastic or dyskinetic cerebral palsy (rs = 0.08; P = 0.43) did not significantly correlate with response percentage. Although injections were usually well tolerated, there were several minor side effects in this series (Table 5).